ETON Eton Pharmaceutical
- 3.650
- -0.010-0.27%
Eton Pharmaceutical News
Eton Pharmaceuticals Q1 2024 GAAP EPS $(0.03) Beats $(0.07) Estimate, Sales $7.966M Miss $8.000M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(
Eton Pharmaceutical | 10-Q: Quarterly report
Eton Pharmaceuticals Expects Continued Sales Growth to Result in Positive Operating Cash Flow Throughout 2024 >ETON
Eton Pharmaceuticals Expects Continued Sales Growth to Result in Positive Operating Cash Flow Throughout 2024 >ETON
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, Vs. Street Est of $8M
04:06 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, vs. Street Est of $8M
Eton Pharmaceuticals 1Q Loss/Shr 3c >ETON
Eton Pharmaceuticals 1Q Loss/Shr 3c >ETON
Press Release: Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results -- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE, launched Nitisinone, and submitted a ne
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) On The Verge Of Breaking Even
Craig-Hallum Initiates Coverage On Eton Pharmaceuticals With Buy Rating, Announces Price Target of $8
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Eton Pharmaceuticals with a Buy rating and announces Price Target of $8.
Eton Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 113.33% Craig-Hallum → $8 Initiates Coverage On → Buy 12/11/2023 166.67% HC Wainwright & Co. →
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle to achieve potential combined peak sales of more than $50 million annually -- Produc
RMBS, SANM and WGS Are Among After Hour Movers
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializin
Eton Pharmaceuticals Entered Agreements To Issue And Sell 1,287,500 Shares Of Common Stock At $3.50/Share And Agreements to Issue Pre-Funded Warrants To Purchase 2,462,500 Shares Of Common Stock
Eton Pharmaceuticals Entered Agreements To Issue And Sell 1,287,500 Shares Of Common Stock At $3.50/Share And Agreements to Issue Pre-Funded Warrants To Purchase 2,462,500 Shares Of Common Stock
CVAC, SBNY and CRMD Are Among After Hour Movers
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the Health Care Select Sector SPDR Fund (XLV) marginally lower recently. Eton Pharmaceuticals (ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersBiolase (NASDAQ:BIOL) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. The market value of their outstanding shares is at $4.6 million. The company's, Q4 earnings came
Sector Update: Health Care
Health care stocks were steady pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the Health Care Select Sector SPDR Fund (XLV) marginally lower recently. Eton Pharmaceuticals (ET
Analysis
Price Target
No Data
